
Telios Pharmaceuticals Names Dr. Juerg Tschopp Senior Director of Research and Development

SAN DIEGO and PLAINSBORO, N.J., Aug. 1 /PRNewswire/ -- Integra LifeSciences Corporation (Nasdaq: [IART](#)) today announced that Dr. Juerg Tschopp, Ph.D., was named Senior Director of Research and Development at Telios Pharmaceuticals, Inc., a wholly owned subsidiary of Integra. He will report directly to Dr. Michael Pierschbacher, Ph.D., Senior Vice President of Research and Development.

In making the announcement, Dr. Pierschbacher said, "Dr. Tschopp rejoins us at Telios bringing extraordinary experience in marketing technology. His proven abilities in marketing and scientific research will help Integra move forward in its goal to maintain the leadership edge in tissue regeneration by expanding peptide-based development programs with pharmaceutical companies."

Dr. Tschopp, who received an MBA in Marketing from San Diego State University, brings his marketing expertise to the Company along with over 20 years experience in scientific research. He will be responsible for directing the enhanced Integra(TM) Artificial Skin projects at San Diego-based Telios. He will also supervise the Small Business Innovative Research (SBIR) sponsored vascular graft project and the continued development of PepTite(TM) Biological Coating, as well as coordinate these efforts with marketing associates at the Company's headquarters in Plainsboro, N.J. In addition, Dr. Tschopp will direct the protein chemistry and assay groups at Telios.

For the past two years, Dr. Tschopp served as Director of Business Development and Marketing for Bubendorf, Switzerland-based Bachem AG, where he supervised joint research projects with client companies and universities. In addition, he initiated new pharmaceutical peptide projects with customers from pharmaceutical and biotechnology companies and coordinated marketing activities for pharmaceutical and research peptides, and biochemicals.

After receiving an M.S. in Chemistry and a Ph.D. in Biochemistry from the University of Basel (Switzerland), Dr. Tschopp built his career with postdoctoral work at the University of California, Berkeley, Calif., and later as a scientist at The Salk Institute Biotechnology/Industry Associates (SIBIA), Inc., in La Jolla, Calif. After seven years at SIBIA, Dr. Tschopp joined the Calbiochem Corporation, also in La Jolla, as Director of Quality Control/Assurance and then became Director of Fermentation Operations. From there, he moved to Telios, where he spent five years in research and development.

"We are delighted to have Juerg back with us again," said Dr. Pierschbacher. "His energy is contagious and his extended marketing experience will be a great asset to our research and development effort."

The Company's first tissue regeneration product, Integra Artificial Skin, is the only FDA approved tissue regeneration medical device that provides immediate wound closure, and regenerates a permanent dermal layer of skin.

Integra LifeSciences Corporation is dedicated to the development and manufacture of proprietary BioSmart(TM) absorbable materials-based therapeutic applications and pharmacological products, which are designed to control the behavior of cells within the patient's body to regenerate tissue that has been irreversibly lost to disease, accident or surgery, or to prevent or cure diseases or age-associated disorders. Integra Artificial Skin is the first of

a series of products that the Company is developing to regenerate a variety of body tissues, including articular cartilage and peripheral nerves, which ordinarily do not regenerate themselves.

Please feel free to visit the company Website (<http://www.integra-ls.com>).

Certain statements made in this press release related to market expansion and acceptance of new and enhanced products, as well as their clinical effectiveness are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may differ materially from those set forth in these statements. In addition, the economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission could affect such results.

SOURCE Integra LifeSciences Corporation

Link to this page:

[back to top](#)

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.

Terms and conditions, including restrictions on redistribution, apply.

Copyright © 1996-2008 PR Newswire Association LLC. All Rights Reserved.

A [United Business Media](#) company.